Cargando…
An intact C-terminal end of albumin is required for its long half-life in humans
Albumin has an average plasma half-life of three weeks and is thus an attractive carrier to improve the pharmacokinetics of fused therapeutics. The half-life is regulated by FcRn, a cellular receptor that protects against intracellular degradation. To tailor-design the therapeutic use of albumin, it...
Autores principales: | Nilsen, Jeannette, Trabjerg, Esben, Grevys, Algirdas, Azevedo, Claudia, Brennan, Stephen O., Stensland, Maria, Wilson, John, Sand, Kine Marita Knudsen, Bern, Malin, Dalhus, Bjørn, Roopenian, Derry C., Sandlie, Inger, Rand, Kasper Dyrberg, Andersen, Jan Terje |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7171077/ https://www.ncbi.nlm.nih.gov/pubmed/32313072 http://dx.doi.org/10.1038/s42003-020-0903-7 |
Ejemplares similares
-
Human and mouse albumin bind their respective neonatal Fc receptors differently
por: Nilsen, Jeannette, et al.
Publicado: (2018) -
Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics
por: Sand, Kine Marita Knudsen, et al.
Publicado: (2015) -
Antibody variable sequences have a pronounced effect on cellular transport and plasma half-life
por: Grevys, Algirdas, et al.
Publicado: (2022) -
A human endothelial cell-based recycling assay for screening of FcRn targeted molecules
por: Grevys, Algirdas, et al.
Publicado: (2018) -
FcRn is a CD32a coreceptor that determines susceptibility to IgG immune complex–driven autoimmunity
por: Hubbard, Jonathan J., et al.
Publicado: (2020)